Ocugen's Gene Therapy Shows 46% Slowdown in Geographic Atrophy Lesions

Ocugen has announced plans to reveal full results from its Phase 2 ArMaDa trial of OCU410, a gene therapy for geographic atrophy. The presentation will take place on March 24, 2026, at 2:00 PM CET. Early findings suggest a 46% reduction in lesion growth after twelve months, raising hopes for a condition with limited treatment options.

The company also reported a 2025 net loss of $67.8 million, despite generating $4.4 million in revenue from licensing deals. Analysts remain optimistic, with Oppenheimer setting a $10 price target and Chardan Capital maintaining a 'Buy' rating.

Ocugen's Phase 2 ArMaDa trial enrolled 60 patients to test OCU410, a gene therapy for geographic atrophy. Interim data from 23 evaluable participants showed a 46% slowdown in lesion growth over a year. Independent clinicians, including Lejla Vajzovic, Jay Chhablani, and Victor H. Gonzalez, will review the findings before the full results are shared.

Geographic atrophy affects an estimated two to three million people in the U.S. and Europe. No approved therapies exist in Europe, and current U.S. treatments provide minimal functional improvement. Ocugen aims to address this gap by launching a Phase 3 trial in mid-2026. The company also plans to submit three Biologics License Applications within the next two years.

Financially, Ocugen secured $22.5 million in January, extending its cash reserves into late 2026. If all outstanding warrants are exercised, funds could last until early 2027. The success of the ArMaDa results will determine whether Ocugen can stick to its regulatory timeline.

The upcoming Phase 2 results will shape Ocugen's next steps in developing OCU410. A positive outcome could accelerate plans for Phase 3 trials and regulatory submissions. With no effective treatments widely available, the therapy's progress is being closely watched by patients and investors alike.